<DOC>
	<DOCNO>NCT00004493</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine pharmacokinetics sodium dichloroacetate ( DCA ) patient congenital lactic acidemia . II . Determine efficacy DCA decreasing frequency and/or severity acute episodes acidotic illness , improve linear growth , improve neurological developmental function , slow neurological developmental deterioration patient .</brief_summary>
	<brief_title>Phase II Pilot Randomized Study Sodium Dichloroacetate Patients With Congenital Lactic Acidemia</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double blind , cross study . Patients randomize start one two different dos sodium dichloroacetate ( DCA ) . Patients receive one two dose oral DCA 6 month , switch alternate dose 6 month . This course repeat . Patients follow 2 year . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Acidosis</mesh_term>
	<mesh_term>Acidosis , Lactic</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis stable , persistent lactic acidemia Venous lactate least 3 mM basal condition define : At least 4 hour postprandial No concurrent illness OR Diagnosis cerebral lactic acidemia elevate lactic acid CSF blood No organic acidemias defective gluconeogenesis Patient Characteristics Hematopoietic : Hemoglobin least 7 mg/dL Hepatic : Bilirubin great 3 time upper limit normal ( ULN ) AST , ALT , GGT great 10 time ULN Renal : Creatinine great 2 mg/dL Cardiovascular : Ejection fraction least 25 % Other : No hypoglycemia ( blood sugar le 50 mg/dL great 12 hour fast ) No severe peripheral neuropathy interfere normal activity live</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2000</verification_date>
	<keyword>inborn error metabolism</keyword>
	<keyword>lactic acidosis</keyword>
	<keyword>rare disease</keyword>
</DOC>